Liraglutide suppresses atrial electrophysiological changes-Reference-Cited by-同舟云学术

Liraglutide suppresses atrial electrophysiological changes

Published:2019-02-14 Issue:8 Volume:34 Page:1389-1393
ISSN:0910-8327
Container-title:Heart and Vessels
language:en
Short-container-title:Heart Vessels

Author:

Nakamura Hironori^ORCID,Niwano Shinichi,Niwano Hiroe,Fukaya Hidehira,Murakami Masami,Kishihara Jun,Satoh Akira,Yoshizawa Tomoharu,Ishizue Naruya,Igarashi Tazuru,Fujiishi Tamami,Ako Junya

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine

Link

http://link.springer.com/article/10.1007/s00380-018-01327-4/fulltext.html

Reference18 articles.

1. Dzeshka MS, Lip GY, Snezhitskiy V, Shantsila E (2015) Cardiac fibrosis in patients with atrial fibrillation: mechanisms and clinical implications. J Am Coll Cardiol 66(8):943–959

2. Igarashi T, Niwano S, Niwano H, Yoshizawa T, Nakamura H, Fukaya H, Fujiishi T, Ishizue N, Satoh A, Kishihara J, Murakami M, Ako J (2018) Linagliptin prevents atrial electrical and structural remodeling in a canine model of atrial fibrillation. Heart Vessels 33(10):1258–1265

3. Lebovitz HE, Banerji MA (2012) Non-insulin injectable treatments (glucagon-like peptide-1 and its analogs) and cardiovascular disease. Diabetes Technol Ther 14:S43–S50

4. Liu Q, Anderson C, Broyde A, Polizzi C, Fernandez R, Baron A, Parkes DG (2010) Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure. Cardiovasc Diabetol 9:76

5. Sonne DP, Engstrøm T, Treiman M (2008) Protective effects of GLP-1 analogues exendin-4 and GLP-1(9–36) amide against ischemia-reperfusion injury in rat heart. Regul Pept 146:243–249

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Obesity and Atrial Fibrillation: Therapeutic Perspective for GLP-1 Analogs;In a good rythm;2024-05-31

2. Metabolic remodelling in atrial fibrillation: manifestations, mechanisms and clinical implications;Nature Reviews Cardiology;2024-05-30

3. Poly-Agonist Pharmacotherapies for Metabolic Diseases: Hopes and New Challenges;Drugs;2023-12-21

4. GLP-1 receptor agonists and myocardial metabolism in atrial fibrillation;Journal of Pharmaceutical Analysis;2023-12

5. Glucagon-like Peptide-1 Receptor Activation Reduces Pulmonary Vein Arrhythmogenesis and Regulates Calcium Homeostasis;International Journal of Molecular Sciences;2023-08-23